Nuwellis Inc vs Wells Fargo & Co — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Wells Fargo & Co trades at $82 (market cap $242.71B). The key difference: Wells Fargo & Co is far larger — about 110322.7× Nuwellis Inc's market cap, and Wells Fargo & Co pays a 2.49% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Wells Fargo & Co for 87 Days on average.
| NUWE | WFC | |
|---|---|---|
Market Cap | $2.20M | $242.71B |
Volume | 121,544 | 13,542,533 |
Sector | Health | Financials |
52-Week High | $146.65 | $96.40 |
52-Week Low | $0.68 | $73.42 |
Typical Hold Time | 26 Days | 87 Days |
Enterprise Value | -$1.52M | $498.47B |
Dividend Yield | — | 2.49% |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Wells Fargo (WFC) trades at $82.06, up 0.67% today, with a bearish technical signal despite recent earnings beat. The stock shows strong fundamentals with 25.97% net income margin and 13.13% ROE, trading at attractive valuations (P/E 11.67, P/B 1.47). Recent credit rating upgrade to 'A-' by S&P and stable Fed stress test changes provide positive catalysts, though negative operating cash flow of -$19B in 2025 raises concerns.
WFC presents a compelling value opportunity with analyst consensus target of $99.13 (21% upside), supported by improving profitability and stable regulatory environment. Key risks include volatile cash flows, rising interest rate pressures, and execution challenges in maintaining recent momentum. The balanced analyst sentiment (47% Buy, 47% Hold) suggests cautious optimism for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →